经导管动脉内介入治疗在晚期胰腺癌中的应用进展  

Application advance of transcatheter interventional treatments in advanced pancreatic cancer

作　　者：李建柯 雷洋洋 田宁子 王小林 LI Jian-ke;LEI Yang-yang;TIAN Ning-zi;WANG Xiao-lin(Shanghai Institute of Medical Imaging,Shanghai 200032,China;Department of Interventional Radiology,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]上海市影像医学研究所,上海200032 [2]复旦大学附属中山医院介入治疗科,上海200032

出　　处：《中国临床医学》2022年第4期701-707,共7页Chinese Journal of Clinical Medicine

基　　金：上海市慈善基金会荣昶专项基金(Q2015-024).

摘　　要：近年来,胰腺癌的发病率呈上升趋势。大多数患者发现时多已处于晚期,生存期短,临床治疗难度大。目前已有大量的基础及临床研究表明经导管动脉内介入治疗能够提高肿瘤组织药物浓度,增强药物抗肿瘤效应,疗效优于全身静脉化疗,不良反应较全身静脉化疗少,已成为治疗晚期胰腺癌的主要手段之一。动脉内介入治疗与其他治疗方式相联合,将成为改善晚期不可切除胰腺癌患者预后的主要治疗模式。随着胰腺癌临床及基础研究不断深入,经动脉介入治疗将会发挥更加重要的作用。The incidence of pancreatic cancer(PC)is increasing recently.The majority of PC patients are diagnosed at an advanced stage,which results in poor response to the treatment and poor prognosis.At present,several studies have shown that transcatheter interventional chemotherapy could increase the local effective drug concentration,and enhance anti-tumor efficacy,which is better than systemic intravenous chemotherapy in terms of efficacy and side effects.Thus,it has become a promising treatment modality for advanced PC.The combination of transcatheter interventional treatments and other treatments will be the main treatment modality that improves the prognosis of patients with PC.With the deepening of clinical and fundamental research of PC,transarterial interventional therapy will play a more important role.

关 键 词：介入治疗 晚期胰腺癌 吉西他滨 氟尿嘧啶 

分 类 号：R736.7[医药卫生—肿瘤]